BIOCRYST PHARMACEUTICALS, INC. Gain (Loss) on Extinguishment of Debt
BIOCRYST PHARMACEUTICALS, INC. (BCRX) reported Gain (Loss) on Extinguishment of Debt of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnExtinguishmentOfDebt · last filed 2026-08-05
- BIOCRYST PHARMACEUTICALS, INC. gain (loss) on extinguishment of debt for the quarter ending 2026-06-30 was $0.00.
- BIOCRYST PHARMACEUTICALS, INC. gain (loss) on extinguishment of debt for the quarter ending 2025-12-31 was -$10.42M.
- BIOCRYST PHARMACEUTICALS, INC. gain (loss) on extinguishment of debt for the quarter ending 2025-09-30 was -$2.74M.
- BIOCRYST PHARMACEUTICALS, INC. gain (loss) on extinguishment of debt for the quarter ending 2025-06-30 was -$4.17M.
- BIOCRYST PHARMACEUTICALS, INC. gain (loss) on extinguishment of debt for fiscal 2025 was -$17.33M.
- BIOCRYST PHARMACEUTICALS, INC. gain (loss) on extinguishment of debt for fiscal 2024 was $0.00.
- BIOCRYST PHARMACEUTICALS, INC. gain (loss) on extinguishment of debt for fiscal 2023 was -$29.02M.
- BIOCRYST PHARMACEUTICALS, INC. gain (loss) on extinguishment of debt for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
| Period end | Gain (Loss) on Extinguishment of Debt 3 month | Gain (Loss) on Extinguishment of Debt 6 month | Gain (Loss) on Extinguishment of Debt 9 month | Gain (Loss) on Extinguishment of Debt 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-05 | $0.00 10-Q · filed 2026-08-05 | ||
| 2025-12-31 | -$10.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$13.16M derived: sum of 2 quarters · filed 2026-02-26 | -$17.33M derived: sum of 3 quarters · filed 2026-08-05 | -$17.33M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$2.74M 10-Q · filed 2025-11-04 | -$6.91M derived: sum of 2 quarters · filed 2026-08-05 | -$6.91M 10-Q · filed 2025-11-04 | |
| 2025-06-30 | -$4.17M 10-Q · filed 2026-08-05 | -$4.17M 10-Q · filed 2026-08-05 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-04 | $0.00 derived: sum of 2 quarters · filed 2025-11-04 | $0.00 10-Q · filed 2025-11-04 | |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-05 | $0.00 10-Q · filed 2025-08-05 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | -$29.02M derived: sum of 3 quarters · filed 2026-02-26 | -$29.02M 10-K · filed 2026-02-26 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-05 | -$29.02M derived: sum of 2 quarters · filed 2024-11-05 | -$29.02M 10-Q · filed 2024-11-05 | |
| 2023-06-30 | -$29.02M 10-Q · filed 2024-08-06 | -$29.02M 10-Q · filed 2024-08-06 | ||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $0.00 derived: sum of 2 quarters · filed 2025-02-25 | $0.00 derived: sum of 3 quarters · filed 2025-02-25 | $0.00 10-K · filed 2025-02-25 |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-08 | $0.00 derived: sum of 2 quarters · filed 2023-11-08 | $0.00 10-Q · filed 2023-11-08 | |
| 2022-06-30 | $0.00 10-Q · filed 2023-08-07 | $0.00 10-Q · filed 2023-08-07 | ||
| 2021-12-31 | $55.84M 10-K · filed 2024-02-27 | |||
| 2020-12-31 | -$2.01M 10-K · filed 2023-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |